IL172365A0 - INHIBITON OF APOPTOSIS-SPECIFIC ELF-5A (" EIF-5A1" ) WITH ANTISENSE OLIGONUCLEOTIDES AND siRNAs AS ANTI-INFLAMMATORY THERAPEUTICS - Google Patents

INHIBITON OF APOPTOSIS-SPECIFIC ELF-5A (" EIF-5A1" ) WITH ANTISENSE OLIGONUCLEOTIDES AND siRNAs AS ANTI-INFLAMMATORY THERAPEUTICS

Info

Publication number
IL172365A0
IL172365A0 IL172365A IL17236505A IL172365A0 IL 172365 A0 IL172365 A0 IL 172365A0 IL 172365 A IL172365 A IL 172365A IL 17236505 A IL17236505 A IL 17236505A IL 172365 A0 IL172365 A0 IL 172365A0
Authority
IL
Israel
Prior art keywords
inhibiton
eif
sirnas
apoptosis
antisense oligonucleotides
Prior art date
Application number
IL172365A
Other languages
English (en)
Original Assignee
Senesco Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senesco Technologies Inc filed Critical Senesco Technologies Inc
Publication of IL172365A0 publication Critical patent/IL172365A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL172365A 2003-06-06 2005-12-05 INHIBITON OF APOPTOSIS-SPECIFIC ELF-5A (" EIF-5A1" ) WITH ANTISENSE OLIGONUCLEOTIDES AND siRNAs AS ANTI-INFLAMMATORY THERAPEUTICS IL172365A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47619403P 2003-06-06 2003-06-06
US50473103P 2003-09-22 2003-09-22
US52824903P 2003-12-10 2003-12-10
US55767104P 2004-03-31 2004-03-31
US57581404P 2004-06-02 2004-06-02
PCT/US2004/018012 WO2005007853A2 (fr) 2003-06-06 2004-06-07 Inhibition d'eif-5a specifique de l'apoptose ('eif-5a1') au moyen d'oligonucleotides antisens et de petits arn interferents utilises comme agents therapeutiques anti-inflammatoires

Publications (1)

Publication Number Publication Date
IL172365A0 true IL172365A0 (en) 2006-04-10

Family

ID=34084831

Family Applications (1)

Application Number Title Priority Date Filing Date
IL172365A IL172365A0 (en) 2003-06-06 2005-12-05 INHIBITON OF APOPTOSIS-SPECIFIC ELF-5A (" EIF-5A1" ) WITH ANTISENSE OLIGONUCLEOTIDES AND siRNAs AS ANTI-INFLAMMATORY THERAPEUTICS

Country Status (9)

Country Link
EP (1) EP1636364A2 (fr)
JP (1) JP5666074B2 (fr)
KR (1) KR20060013428A (fr)
AU (1) AU2004258070B2 (fr)
CA (1) CA2528372A1 (fr)
IL (1) IL172365A0 (fr)
NZ (2) NZ544159A (fr)
TW (1) TW200512293A (fr)
WO (1) WO2005007853A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381708B2 (en) 2001-07-23 2008-06-03 Sensco Technologies, Inc. Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
EP1601767B1 (fr) 2003-03-05 2012-04-25 Senesco Technologies, Inc. Utilisation de siarn pour supprimer l'expression de eif-5a1 dans le traitement du glaucome
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
US20140371299A1 (en) * 2004-06-07 2014-12-18 Senesco Technologies, Inc. Use of Apoptosis-Specific elF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis
EP1769075A2 (fr) * 2004-07-20 2007-04-04 Senesco Technologies, Inc. Utilisation d'arnsi eif-5a specifiques de l'apoptose et de polynucleotides antisens pour inhiber/supprimer une reponse inflammatoire
NZ556236A (en) * 2004-12-03 2009-12-24 Senesco Technologies Inc Apoptosis-specific eIF-5A and polynucleotides encoding same
WO2007070824A2 (fr) * 2005-12-13 2007-06-21 Senesco Technologies, Inc. Utilisation d'eif-5a pour detruire les cellules d'un myelome multiple
EP1996707A2 (fr) * 2006-03-20 2008-12-03 Senesco Technologies, Inc. Nouvelle méthode pour la protection d'îlots de langerhans de l'apoptose au cours du processus de prélèvement chez un donneur
KR20080082688A (ko) * 2006-03-20 2008-09-11 세네스코 테크놀로지스 인코포레이티드 공여자의 섬 세포 채취 과정 동안에 섬 세포를아폽토시스로부터 보호하는 신규 방법
KR20080070879A (ko) * 2006-03-20 2008-07-31 세네스코 테크놀로지스 인코포레이티드 패혈증 또는 출혈성 쇼크를 치료하기 위한 ｅＩＦ-5Ａ1ｓｉＲＮＡ 및 안티센스의 용도
WO2007115047A2 (fr) * 2006-03-29 2007-10-11 Senesco Technologies, Inc. INHIBITION DE LA RÉPLICATION DU VIH ET DE L'EXPRESSION DE p24 PAR LE BIAIS D'elF-5
US20090093434A1 (en) * 2007-08-20 2009-04-09 Senesco Technologies, Inc. Use of eif-5a1 sirna to protect islets cells from apoptosis and to preserve their functionality
CN102282259A (zh) 2008-03-07 2011-12-14 森尼斯科技术公司 与有义构建体实现期望多核苷酸的表达的用途相组合的、sirna实现内源基因的减量调节的用途
WO2009144933A1 (fr) * 2008-05-27 2009-12-03 国立大学法人東京大学 Inducteur de l'apoptose
US8445638B2 (en) 2008-09-03 2013-05-21 Senesco Technologies, Inc. Use of a truncated eIF-5A1 polynucleotide to induce apoptosis in cancer cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1173897A (zh) * 1995-02-13 1998-02-18 诺瓦蒂斯有限公司 真核起始因子5A(eIF－5A)突变体
CA2448320A1 (fr) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Modulation a base de l'acide nucleique des maladies et troubles de l'appareil reproducteur chez la femme
US7968523B2 (en) * 2001-07-23 2011-06-28 Senesco Technologies, Inc. Method for inducing apoptosis using apoptosis-specific EIF5-A
US7381708B2 (en) * 2001-07-23 2008-06-03 Sensco Technologies, Inc. Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
DK2280070T3 (en) * 2001-07-23 2015-08-24 Univ Leland Stanford Junior Methods and compositions for use in RNAi-mediated inhibition of gene expression in mammals
US7166467B2 (en) * 2001-07-23 2007-01-23 Senesco Technologies, Inc. Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
EP1601767B1 (fr) * 2003-03-05 2012-04-25 Senesco Technologies, Inc. Utilisation de siarn pour supprimer l'expression de eif-5a1 dans le traitement du glaucome

Also Published As

Publication number Publication date
JP2006526989A (ja) 2006-11-30
AU2004258070A1 (en) 2005-01-27
JP5666074B2 (ja) 2015-02-12
AU2004258070B2 (en) 2008-12-11
NZ574973A (en) 2010-10-29
TW200512293A (en) 2005-04-01
CA2528372A1 (fr) 2005-01-27
WO2005007853A2 (fr) 2005-01-27
NZ544159A (en) 2009-04-30
EP1636364A2 (fr) 2006-03-22
KR20060013428A (ko) 2006-02-09
WO2005007853A3 (fr) 2005-10-27

Similar Documents

Publication Publication Date Title
IL172365A0 (en) INHIBITON OF APOPTOSIS-SPECIFIC ELF-5A (" EIF-5A1" ) WITH ANTISENSE OLIGONUCLEOTIDES AND siRNAs AS ANTI-INFLAMMATORY THERAPEUTICS
HK1257506A1 (zh) 靶向連接蛋白的反義化合物及其使用方法
ZA200600387B (en) Hydrolytically-resistant bornon-containing therapeutics and methods of use
GB2442373B (en) Sequence -specific inhibition of small rna function
PT2056845T (pt) Estrutura e uso de oligonucleótidos com fosfato 5
EP1951736A4 (fr) Arns interferents de multiciblage et methodes d'utilisation et de conception
EP1639086A4 (fr) Arn interferases et leurs procedes d'utilisation
EP1487980A4 (fr) Arn modifie de silen age genique et utilisations associees
SI3385384T1 (sl) Aptamerni terapevtiki, uporabni v zdravljenju s komplementom povezanih motenj
EP1539778A4 (fr) Deprotection et purification d'oligonucleotides et de leurs derives
RS56361B1 (sr) Sinteza zaštićenih 3'-amino nukleozidnih monomera
EP1640452A4 (fr) Arn oligobicatenaire inhibant l'expression de bcl-2 et composition medicinale contenant cet arn
EP1453837A4 (fr) Agents therapeutiques cibles et leurs utilisations
AU2003299864A8 (en) Sirna compounds and methods for the downregulation of gene expression
EP1609005A4 (fr) Procede pour determiner des proprietes d'un corps sedimentaire a partir de l'epaisseur et de la granulometrie en un point dudit corps
AU2003278202A8 (en) Inhibition of gene expression in vertebrates using double-stranded rna (rnai)
EP1666593A4 (fr) Molecules d'arnsi amelioree et technique d'inhibition de l'expression de gene au moyen de celle-ci
EP1605814A4 (fr) Ecarteur equipe de moyens de guidage et ses methodes d'utilisation
EP1590440A4 (fr) Molecules d'elimination de cellules et methodes d'utilisation associees
EP1625141A4 (fr) Compositions a base de grp94 et procedes d'utilisation associes
AU2003239864A1 (en) Antisense moodulation of kinesin-like 1 expression
EP1738771A4 (fr) ARNsi CAPABLE D'INHIBER L'EXPRESSION DU GENE WT1 ET UTILISATION DE CELUI-CI
EP1633850A4 (fr) Compositions d'anticorps ovr115 et procedes d'utilisation
AU2003218555A1 (en) Combinations of antisense oligonucleotides directed against thymidylate synythase mrna and uses thereof
HK1073141A1 (en) Use of fiber structure having anti-trichomonad and anti-spores of trichomonad property